Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
1.
Rheumatol Int ; 42(3): 441-448, 2022 03.
Article in English | MEDLINE | ID: mdl-33146762

ABSTRACT

MASEI is the main validated ultrasound score for the evaluation of enthesis. The lack of studies facing the agreement to achieve for the interpretation of the MAdrid Sonographic Enthesis Index (MASEI) among researchers from different centers in multicenter studies is of concern. The aim of this multicenter was to evaluate the interobserver reliability of MASEI. An experienced ultrasonographer-rheumatologist performed ultrasound scans of the areas included in MASEI index in three patients with Ankylosing Spondylitis and Psoriatic Arthritis. Videos were captured. The videos were then evaluated by 24 rheumatologists of the ultrasound working group of the Catalan Society of Rheumatology (EcoCAT). A face-to-face training meeting was held. Ten days after the workshop, the study participants evaluated the videos. A reliability assessment was performed. The ICC for the MASEI scores after the workshop was of 0.97 (95% CI 89-99). Reliability did not vary statistically with examiner experience. Globally, no problems of reliability by structures were seen, and all the ICCs were above 0.90 and improved slightly after the educational program. However, the correlation observed between examiners at plantar aponeursis and triceps tendon was weak. The small variability observed in the results of the index validation in our study, suggests that the MASEI index is reproducible by different observers when those are well trained and show awesome results of the enthesis when examined by ultrasound.


Subject(s)
Musculoskeletal System/diagnostic imaging , Spondylarthropathies/diagnostic imaging , Ultrasonography/methods , Adult , Aged , Female , Humans , Male , Observer Variation , Reproducibility of Results , Rheumatology/education , Rheumatology/methods , Severity of Illness Index
2.
J Clin Endocrinol Metab ; 88(5): 2141-6, 2003 May.
Article in English | MEDLINE | ID: mdl-12727967

ABSTRACT

Retrospective studies have shown antineutrophil cytoplasmic antibody (ANCA) positivity in patients treated for Graves' hyperthyroidism; ANCA has been attributed to either antithyroid drugs or to the disease itself. The aim of this study was to determine ANCA in Graves' disease patients at diagnosis and after treatment with methimazole and to evaluate the relationship between ANCA and hyperthyroidism evolution. Thirty patients recently diagnosed with Graves' hyperthyroidism were prospectively studied. ANCA were determined by indirect immunofluorescence. ANCA autoantibodies against specific antigens (proteinase 3, myeloperoxidase, bactericidal/permeability-increasing protein (BPI), cathepsin, lysozyme, elastase, and lactoferrin) were detected by ELISA. The median observation period was 22 months. Kaplan-Meier analysis was performed to identify ANCA as an outcome variable. Twenty patients (67%) were ANCA positive before the onset of treatment, and four (19%) remained positive after 1 yr of antithyroid drug treatment. No differences were observed in any clinical or analytical features between patients with or without positive ANCA. Before treatment, BPI-positive patients required radioiodine treatment or presented relapse more rapidly than BPI-negative patients (log-rank test P < 0.0002). Patients with Graves' hyperthyroidism show positive ANCA before medical treatment, which points to a relationship with the autoimmune disease itself. Our results suggest that BPI-positive patients tend to relapse with antithyroid medication.


Subject(s)
Antibodies, Antineutrophil Cytoplasmic/blood , Antithyroid Agents/therapeutic use , Graves Disease/drug therapy , Graves Disease/immunology , Membrane Proteins , Methimazole/therapeutic use , Adult , Antibody Specificity , Antimicrobial Cationic Peptides , Blood Proteins/immunology , Enzyme-Linked Immunosorbent Assay , Female , Fluorescent Antibody Technique, Indirect , Graves Disease/radiotherapy , Humans , Iodine Radioisotopes/therapeutic use , Male , Middle Aged , Myeloblastin , Peroxidase/immunology , Prognosis , Prospective Studies , Recurrence , Serine Endopeptidases/immunology
SELECTION OF CITATIONS
SEARCH DETAIL
...